Zydus Lifesciences shares surged over 3% after the company announced the launch of Mirabegron Extended-Release Tablets, 25 mg, in the US market. Zydus had earlier received final approval from the United States Food and Drug Administration (USFDA) to market Mirabegron Extended-Release Tablets USP 25 mg and 50 mg.
The company is among the first suppliers to launch the generic version of Mirabegron Extended-Release Tablets, USP 25 mg, in the US market. Zydus is prepared to launch Mirabegron Extended-Release Tablets, 50 mg, imminently.
Mirabegron is indicated for the treatment of overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency, and urinary frequency. The drug will be manufactured at the group’s formulation manufacturing facility in Ahmedabad SEZ, India.
As of 11:55 am, Zydus Lifesciences shares were trading 3% higher at ₹949.95 on the National Stock Exchange (NSE), reflecting the market’s positive response to the company’s US launch.
